3
Introduction
Vertebrate bone is formed through either intramembranous or endochondral ossification. The intramembranous bone is directly formed by osteoblasts, whereas the cartilaginous bone is initially formed by chondrocytes at the endochondral ossification. The cartilage is then replaced with bone by a repeated remodeling process mediated with osteoblasts and osteoclasts. 1 In endochondral ossification, chondrocytes undergo a process of proliferation and maturation. Maturation process of chondrocytes is defined by the expression of specific extracellular matrix genes. Prechondrogenic cells express type I collagen, and the induction of type II collagen occurs with the change of cellular phenotype from prechondrogenic cells to proliferating chondrocytes. 2 Hypertrophic chondrocytes then express various proteins such as type X collagen. Matrix metalloproteinase (MMP)-13 contributes to the calcification process of surrounding matrix. 3 Runt-related gene 2 (Runx2), a potent transcripti on factor, belongs to the runt domain gene family. 4 , 5 It has been shown that endochondral ossification is completely blocked when chondrocyte maturation is disturbed in Runx2-deficient mice, 6 , 7 whereas Runx2 overexpression promoted maturation process of chondrocytes in Cbfa1 transgenic mice. 8 Expression of Runx2 mRNA was upregulated prior to the differentiation toward the hypertrophic phenotype, which indicated that Runx2 may be related to the maturation of hypertrophic chondrocytes in ATDC5 cells in vitro. 9 From these findings, Runx2 is assumed to be an essentially indispensable factor for chondrocyte differentiation or maturation.
In previous studies, a large amount of hyaluronan (HA) was detected around hypertrophic chondrocytes.
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The pericellular matrix surrounding hypertrophic chondrocytes is composed of both HA and aggrecan, and attaches to the surfaces of chondrocytes through HA binding proteins. 1 2 Due to this structure, high molecular weight-HA (HMW-HA) is capable of absorbing a large amount of water, and its function allows it to exert hydrostatic pressure on the surrounding tissue. 1 3 In addition, HA function is enhanced by activation of HA receptors such as CD44. 1 4 It has also been shown that signal transduction of HMW-HA is performed through the activation of Smad proteins in the BMP-7 signaling pathway in chondrocytes. 1 5 Conversely, HA oligosaccharide (HAoligo), such as HA hexasaccharides (HA 6 ) induce MMP-3 via retinoid and/or NF-κB signaling pathway in chondrocytes. 1 6 Therefore, HA may have a signaling function through chondrocyte differentiation that is dependent on its molecular weight. Although a crucial role of HA at the hypertrophic stage has been speculated, the effects of HA as a signaling molecule during chondrocyte differentiation remain unclear.
The aim of this study is to clarify the effects of HMW-HA and HAoligo on the expression and activity of Runx2 at the hypertrophic chondrocytes through the endochondral ossification process.
Materials and methods

Cell culture
A mouse chondrogenic cell line, ATDC5, was purchased from the RIKEN Cell Bank (Tsukuba Science City, Japan). ATDC5 cells were cultured in DMEM/Ham's F12 hybrid medium (Sigma, St. Louis, MO, USA) containing 5% fetal bovine serum (FBS) (Mitsubishi Kagaku, Tokyo, Japan), 10 μ g/ml human transferrin (Sigma) and 3×10 -8 M sodium selenite (Sigma) at 37˚C in a humidified atmosphere with 5% CO 2 in air. To induce chondrogenesis, ATDC5 cells were seeded at a density of 6×10 4 cells/well onto six well plates and cultured for 18 days in the above-mentioned medium supplemented with 10 μg/ml bovine insulin (Sigma).
Quantitative real-time PCR analysis
Total RNA was extracted from cultured ATDC5 cells using a Total RNA Extraction Kit R (Pharmacia Biotech, Tokyo, Japan) every 3 days after the cells became confluent. The first strand cDNA was synthesized from 1 μg total RNA using a ReverTra Ace-α first-strand cDNA synthesis kit (Toyobo, Osaka, Japan 
Alizarin red and alkaline phosphatase (ALP) staining
To detect calcium accumulation, ATDC5 cells cultured for 18 days were fixed with 2% neutralized formaldehyde solution and stained with 1% alizarin red (pH6.3) as previously described 1 7 . Alkaline phosphatase (ALP) staining was also performed for cultured ATDC5 cells on day 18 using fast 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium tablets (Sigma).
Immunostaining
Articular cartilage was removed from the TMJ of a 10-week-old rat. After fixation in 4% paraformaldehyde, 
Preparation of HAoligo
HAoligo was refined according to the method established by Knudson et al. 1 8 , 1 9 Treatment with HMW-HA, HAoligo ATDC5 cells were seeded at a density of 6×10 4 cells/well in six-well plates and cultured for 18 days (confluent on day 0). On day 18, which corresponds to the hypertrophic stage, ATDC5 cells were treated with phosphate buffered saline (PBS), serving as the control. These cells were then treated with 250 μ g/ml purified HMW-HA of 1.2× 10 5 Da (Seikagaku Corporation, Tokyo, Japan), 250 μ g/ml HAoligo for 12 hrs with or without preincubation of 1.0 μ g/ml anti-CD44-neutralizing antibody (IM7.8.1 mAb: ENDOGEN, Woburn, MA, USA) for 1 hr. The optimal treatment time of ATDC5 cells was defined by a preliminary experiment (data not shown).
Measurement of Runx2 activity
Nuclear proteins were extracted from the experimental and control cultures of ATDC5 cells on day 18 using a Nuclear Extraction Kit (Sigma). The cells were collected in ice-cold PBS in the presence of phosphatase inhibitors, and resuspended in hypotonic buffer. Cytoplasmic fractions were collected by centrifugation at 14,000 rpm for 30 s in a microfuge after the addition of detergent. Then, the nuclei were placed in a lysis buffer in the presence of the protease inhibitor and separated from insoluble material s by centrifugation. Nuclear extracts were quantified by bicinchoninic acid (BCA) protein assay and stored at -80 ˚C.
The activity of Runx2 was measured using a TransAM AML-3/Runx2 Kit (Sigma) according to the manufacturer's instructions. Briefly, 3 μ g nuclear protein samples were incubated for 1 hr in a 96-well plate coated
with an oligonucleotide containing a Runx2 consensus binding site, to which activated Runx2 in nuclear extracts specifically binds. After washing, Runx2 antibody was added to these wells and incubated for 1 hr. Following further incubation with a secondary HRP-conjugated antibody, specific binding was detected by colorimetric estimation at 450 nm with a reference wavelength of 655 nm.
Western blot analysis
ATDC5 cells were lysed in 50 mM Tris, pH 7.5, with 250 mM NaCl, 0.1% Triton-X-100 buffer, 1mM EDTA and 50 mM NaF with phosphatase inhibitors. 20 μg of protein was separated on 8.0% gel by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Whatman, Dassel, Germany). After blocking the membrane with 5% milk, the membrane was incubated with Runx2 monoclonal antibody (Medical & Biological Laboratories, Nagoya, Japan, dilution 1:1000) or β-actin peptide mAb (AC-15; Sigma, dilution 1:1000) detected with horse radish peroxidase (HRP)-conjugated secondary antibody (dilution 1:1000) and ECL reagents (Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom).
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MMP-13 mRNA level increased again, and reached a significantly higher level than the control. These findings indicated that the hypertrophic stage of ATDC5 cells occurred between days 15 and 18.
The Runx2 mRNA level increased from day 6, reached a maximum on day 12, and then rapidly decreased to the control level (Fig. 1D) . From day 15 to day 18, defined as the hypertrophic stage, Runx2 mRNA increased to a significantly higher level.
The HAS2 mRNA level at the matrix-forming stage was relatively low (Fig. 1E) . From day 12, the HAS2 mRNA level increased, and reached a maximum on day 15, defined as the pre-hypertrophic stage.
ALP activity and matrix calcification in cultured ATDC5 cells at the hypertrophic stage
We next examined whether ATDC5 cells in the hypertrophic stage expressed the hypertrophic phenotype, characterized by ALP activity and matrix calcification. ATDC5 cells on day 18 showed very high levels of ALP activity and matrix calcification, while the control cultures on day 0 showed very low levels of ALP activity and no matrix calcification (Fig. 2) .
Distribution of Runx2 in temporomandibular joint (TMJ) condyle cartilage
Runx2 was highly expressed in the nuclear region of chondrocytes in the maturation and hypertrophic layers (Fig. 3B) . The distribution of Runx2 in differentiating cartilage was coincident with gene expression of Runx2 in differentiating ATDC5 cells.
Effects of HAoligo on pericellular matrix around ATDC5 cells
A particle-exclusion assay was used to determine if ATDC5 cells were capable of producing and organizing HA-rich pericellular matrices. In this assay, the presence of a pericellular matrix can be visualized by the exclusion of fixed red blood cells from a clear, halo-like area adjacent to the cell (Fig. 4A) . Pericellular matrix was removed by treatment with both HAoligo (Fig. 4B) .
Effects of HMW-HA and HAoligo on Runx2 expression and activity in cultured ATDC5 cells at the hypertrophic stage
Runx2 mRNA expression was significantly suppressed in cultured ATDC5 cells at the hypertrophic stage by the treatment with HAoligo (p< 0.01) when compared to the untreated control (Fig. 5A ). In particular, HAoligo decreased the expression of Runx2 mRNA most significantly, to less than half of the control level. Meanwhile, no significant effects of HMW-HA were found on Runx2 mRNA expression (Fig. 5A ).
The expression of Runx2 protein was evaluated using Western blot analysis. An immunoreactive band of 55kDa was observed, which corresponding to Runx2 (Fig. 5B) . The treatment of HAoligo prominently decreased Runx2 protein expression, while Runx2 protein exhibited a tendency to decrease by the treatment with HMW-HA.
Runx2 activity was significantly decreased in cultured ATDC5 cells at the hypertrophic stage by the treatment with HAoligo as compared to the untreated control (p<0.05). Meanwhile, Runx2 activity exhibited a tendency to decrease, but not significant, with the treatment of HMW-HA (Fig. 5C ).
Effects of HMW-HA, HAoligo, and anti-CD44 neutralizing antibody on Runx2 expression in cultured ATDC5 cells at the hypertrophic stage
Runx2 mRNA expression significantly decreased in cultured ATDC5 cells at the hypertrophic stage by the treatment with anti-CD44 neutralizing antibody alone (p<0.01). Furthermore, anti-CD44 neutralizing antibody treatment, followed by addition of HAoligo and HMW-HA, decreased the expression of Runx2 mRNA (Fig. 6 ). The addition of HMW-HA significantly restored the expression of Runx2 which decreased with the treatment of anti-CD44 neutralizing antibody (p<0.05) (Fig. 6) .
Effects of HMW-HA, HAoligo, and anti-CD44 neutralizing antibody on chondrogenic markers gene expression in cultured ATDC5 cells at the hypertrophic stage
Type II collagen mRNA expression was significantly decreased by the treatment of anti-CD44 neutralizing antibody, while type II collagen mRNA expression exhibited a tendency to decrease, but not significantly, by the treatment with HMW-HA (Fig. 7A) . Furthermore, type II collagen mRNA expression was unchanged by the treatment with HAoligo.
Type X collagen mRNA expression was significantly decreased by treatment with HAoligo and anti-CD44 neutralizing antibody treatment (Fig. 7B ).
MMP-13 mRNA expression was significantly decreased by the treatment with HAoligo, while no significant effects of HMW-HA and anti-CD44 neutralizing antibody were found on Runx2 mRNA expression (Fig. 7C ).
Discussion
Cultures of ATDC5 cells have been shown to be a useful in vitro model for examining the differentiation of chondrocytes. Cultured in the presence of insulin, ATDC5 cells form many spots of cartilage-like cellular condensation, and they are able to differentiate to hypertrophic chondrocytes. Meanwhile, we have showed that type X collagen mRNA markedly increased from day 15 to 18. Because type X collagen is synthesized specifically by hypertrophic chondrocytes, induction of type X collagen mRNA is regarded as a signal of the differentiation from proliferating to hypertrophic ones.
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It was also clarified that both MMP-13 and Runx2 increased during this period. Runx2 is well known to upregulate the expression of the gene promoters related to MMP-13 and bone matrix proteins including osteopontin (OPN) and bone sialoprotein (BSP). 1 , 2 6 These results indicated that the expression of both Runx2 and MMP-13 mRNAs in ATDC5 cells markedly increased from day 15, suggesting an initiation of the hypertrophic stage. In the hypertrophic stage, ATDC5 cells showed very high levels of ALP activity and matrix calcification.
We also investigated the distribution of Runx2 in mandibular condylar cartilage, and found that Runx2 was distributed widely in the maturation and hypertrophic layer coincident, with gene expression of Runx2 in cultured AT DC5 ce ll s.
With respect to the effect of HA on Runx2 activity, we have shown that HMW-HA had no significant effects on gene expression and activity of Runx2. In process of chondrocyte differentiation, the gene expression and synthesis of HA are increased at the hypertrophic stage in cultured chondrocytes. 1 0 Magee et al. 2 7 reported that HA synthesis was elevated in the hypertrophic zone, along with the up-regulation of HAS2 mRNA and the activation of UDP-glucose pyrophosphorylase (UDPG-PPase) in the developing growth plate chondrocytes. The present study
showed that the gene expression of HAS2, which is well known to lead to HMW-HA synthesis, was up-regulated after the matrix-forming stage and at the pre-hypertrophic stage in cultured ATDC5 cells. The up-regulation of the HAS2 gene generated a considerable increase in HMW-HA synthesis in hypertrophic chondrocytes. 1 0 From these findings, it would be reasonably assumed that HAS2 and HMW-HA exert anabolic functions for chondrocytes and the pericellular matrices, leading to no suppression of gene expression and activity of Runx2.
On the other hand, the treatment with HAoligo suppressed both gene expression and activity of Runx2. This result supports a hypothesis that HAoligo is an active mediator for the response of chondrocyte by either transmitting a signal directly through CD44 or disrupting HA-CD44 interactions. Knudson et al. 1 8 , 2 8 revealed that the cell-matrix interactions in chondrocytes were inhibited by the treatment with excessive small HAoligo, such as HA 6 . It is also shown that HAoligo induces MMP-3 via the retinoid and/or NF-κ B signaling pathway in chondrocytes. 1 6 Furthermore, HAoligo induced the activation of NF-κ B, (MAP)-kinases, protein kinase C (PKC), G-protein, and PI3 kinase in other cells. 2 9 -3 3 From these results, it is suggested that HAoligo might have a signaling function through chondrocyte differentiation.
These results indicate have shown that Runx2 gene expression was significantly decreased in cultured ATDC5 cells at the hypertrophic stage treated with anti-CD44 neutralizing antibody alone. However, HAoligo had no synergistic effect of anti-CD44 neutralizing antibody on the down-regulation of Runx2 mRNA, comparing to anti-CD44 neutralizing antibody alone. Taking it into consideration that HAoligo down-regulates the expression and activity of Runx2, it is probable that HAoligo transduces some signals through CD44.
It has been previously shown that HA 6 was effective at preventing formation of HA-dependent pericellular matrices in other cells. 2 1 In this study we have shown that HAoligo decreased HA-dependent pericellular matrices in ATDC5 cells. Furthermore, anti-CD44 neutralizing antibody treatment followed by addition of HAoligo and HMW-HA decreased the expression of Runx2 mRNA. The addition of HMW-HA significantly restored the expression of Runx2, which decreased with the treatment of anti-CD44 neutralizing antibody. In addition, it has been reported that HAoligo competes for binding of HMW-HA to the cell surface. 3 4 , 3 5 Given that HMW-HA is bound to CD44 in this study, HMW-HA likely prevents the novel binding of low molecular weight-HA to CD44, and maintains chondrocyte differentiation of hypertrophic stage.
In this study, the expression of Type X collagen and MMP-13 mRNA in cultured ATDC5 cells at the hypertrophic stage significantly decreased with the treatment of HAoligo, while type II collagen mRNA expression was unchanged with the treatment of HAoligo. Previous studies have suggested that chondrocytes promote type X collagen mRNA expression and concomitantly decrease expression of type II collagen mRNA in the cell hypertrophy. 3 6 In addition, MMP-13 is associated with both chondrocyte hypertrophy and with matrix vesicles implicated in cartilage matrix mineralization. 3 7 , 3 8 It has also been reported that Runx2 is able to induce the expression of MMP-13. 3 6 Therefore, the decrease of Runx2 expression by HAoligo treatment might downregulate chondrocyte differentiation at the hypertrophic stage.
In conclusion, a new finding in this study was that HAoligo suppressed the gene expression and activity of Runx2 through CD44 in hypertrophic chondrocytes. In addition, HAoligo may contribute to the inhibition of endochondral ossification by blocking the hypertrophy of chondrocytes. Alkaline phosphatase (ALP) staining was also performed for cultured ATDC5 cells on day 18 using fast 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium tablets. 
